A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2029-07-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.